BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lonza Group Files Patent Infringement Lawsuit Against Nutraceutical International Corporation


10/19/2005 5:10:52 PM

FAIR LAWN, N.J., April 12 /PRNewswire/ -- Lonza Ltd. filed suit in the District Court for the Southern District of New York against Nutraceutical International Corporation and several of its subsidiaries for infringement of Lonza Ltd.'s U.S. Patent No. 5,073,376. Nutraceutical markets products under the trademarks Kal, Nature's Life, Solaray and Natural Max.

The subject patent covers enteric preparations of L-Carnitine L-Tartrate. The validity of all of the claims of the Lonza patent was recently confirmed during re-examination by the U.S. Patent and Trademark Office.

Lonza is a leader in the industry in promoting the nutritional uses of L-Carnitine, a nutrient beneficial for weight loss, athletic performance and general cardiovascular health. Lonza has devoted substantial ingenuity and resources to develop its patent and trademark portfolio for the nutritional uses of L-Carnitine. This suit is the first action brought by Lonza Ltd. against a manufacturer of products containing unlicensed L-Carnitine L-Tartrate, and represents a major step in Lonza's continuing efforts to maintain and enforce its patent rights in the L-Carnitine market.

Lonza is a life sciences driven company, headquartered in Switzerland, which generated sales of CHF 2.24 billion in 2003. It operates 18 production and R&D facilities in eight countries and employs 5,660 people worldwide. Lonza is one of the leading custom manufacturers of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries. In addition, Lonza also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermediates and compounds. For more information please visit the company's websites at http://www.lonza.com/ or http://www.carnitine.com/.

Lonza Ltd.

CONTACT: Reto Rieder, Director Nutrition, +1-201-794-2649, or fax,+1-201-794-2695, reto.rieder@lonza.com, or Christine Casper, CommunicationsManager, +1-201-794-2448, or fax, +1-201-794-2695, christine.casper@lonza.com,both of Lonza Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES